BIOCRYST PHARMACEUTICALS INC (BCRX)       10.58  -0.2 (-1.86%)

10.58  -0.2 (-1.86%)

US09058V1035 - Common Stock - After market: 10.74 +0.16 (+1.51%)


Fundamental Rating

3

Taking everything into account, BCRX scores 3 out of 10 in our fundamental rating. BCRX was compared to 639 industry peers in the Biotechnology industry. The financial health of BCRX is medium. Also its profitability is quite bad. BCRX is valued quite expensive, but it does show an excellent growth.

Note: BCRX has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of BCRX is 3.00. This is a low score and indicates issues in the health and profitability of BCRX.

VS Industry

Valuation

Valuation Rating

0

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

8

The Earnings Per Share has grown by an nice 17.32% over the past year.
The Earnings Per Share is expected to grow by 20.87% on average over the next 5 years. This is a very strong growth
Looking at the last year, BCRX shows a very strong growth in Revenue. The Revenue has grown by 109.10%.

BCRX shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 42.93% yearly.
The Revenue is expected to grow by 31.98% on average over the next 5 years. This is a very strong growth
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 17.32% -9.84% 7.85% 21.85% 20.87%
Revenue42.93% 96.71% 109.1% 69.55% 49.97% 41.03% 31.98%

Health

Health Rating

4

A Current Ratio of 6.23 indicates that BCRX has no problem at all paying its short term obligations.
A Quick Ratio of 5.90 indicates that BCRX has no problem at all paying its short term obligations.
BCRX has a Current Ratio comparable to the industry average, which is at 6.21.
BCRX has a Quick Ratio comparable to the industry average, which is at 6.11.

BCRX has a Altman-Z score comparable to the industry average, which is at -0.13.
BCRX has an Altman-Z score of -1.56. This is a bad value and indicates that BCRX is not financially healthy and even has some risk of bankruptcy.
The Piotroski-F score of BCRX is 3.00. This is a low score and indicates issues in the health and profitability of BCRX.
VS Industry

Quick Ratio (5.9) VS Industry: 48% outperformed.

0.04
84.53

Current Ratio (6.23) VS Industry: 50% outperformed.

0.08
85.09

Altman-Z (-1.56) VS Industry: 42% outperformed.

-94.22
622.88

Dividend

Dividend Rating

0

BCRX does not give a dividend.

BIOCRYST PHARMACEUTICALS INC10.58

NASDAQ:BCRX (1/27/2023, 7:00:00 PM)-0.2 (-1.86%)

After market: 10.74 +0.16 (+1.51%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-21 2023-02-21
Inst Owners 79.54% Inst Owner Change -0.06%
Ins Owners 1.42% Ins Owner Change 13.49%
Market Cap 1.97B Analysts 74.44
Price Target 16.09 (52.08%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 2 Avg EPS beat(2) 15.54%
Min EPS beat(2) 8.62% Max EPS beat(2) 22.47%
EPS beat(4) 3 Avg EPS beat(4) 22.95%
Min EPS beat(4) -7.1% Max EPS beat(4) 67.82%
Revenue beat(2) N/A Avg Revenue beat(2) -0.24%
Min Revenue beat(2) -0.38% Max Revenue beat(2) -0.09%
Revenue beat(4) N/A Avg Revenue beat(4) -2.96%
Min Revenue beat(4) -6.67% Max Revenue beat(4) -0.09%
PT rev (1m) -6.08% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) 0%
Revenue NY rev (1m) 0%

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.27
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM) -1.05 EY N/A
EPS(NY) -0.86 Fwd EY N/A
FCF(TTM) -0.92 FCFY N/A
OCF(TTM) -0.91 OCFY N/A
SpS 1.28 BVpS -1.3
TBVpS -1.3 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 98.11%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -0.81% GM growth 5Y 1.22%
F-Score 3 Asset Turnover 0.43

Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.49%
Profit Quality N/A
Current Ratio 6.23
Quick Ratio 5.9
Altman-Z -1.56
F-Score 3 WACC 9.3%
ROIC/WACC N/A Cap/Depr(3y) 140.72%
Cap/Depr(5y) 103.47% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 17.32% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 30.3%
EPS Next Y -9.84% EPS Next 2Y 7.85%
EPS Next 3Y 21.85% EPS Next 5Y 20.87%
Revenue growth 1Y 109.1% Revenue growth 3Y 96.71%
Revenue growth 5Y 42.93% Revenue growth Q2Q 84.97%
Revenue Next Year 69.55% Revenue Next 2Y 49.97%
Revenue Next 3Y 41.03% Revenue Next 5Y 31.98%
EBIT growth 1Y 13.29% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year 26.38%
EBIT Next 3Y 30.13% EBIT Next 5Y N/A
FCF growth 1Y -66.63% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -65.46%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA